Security
CMND · Clearmind Medicine Inc.
CMNDNASDAQCommon stockCurrentCIK 1892500Updated Sep 24, 2026
CMND price & chart
Loading TradingView…
NASDAQ:CMND on TradingView ↗About the company
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
In the news
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -3,856,983Source | -5,254,678Source | -8,620,837Source | -9,410,806Source |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodUSD | -32,177Source | -384,109Source | — | — |
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableCAD | — | — | — | 27,214Source |
| AdjustmentsForIncomeTaxExpenseUSD | 70,445Source | 103,879Source | — | — |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | 82,788Source | -198,590Source | -620,421Source | 1,246,570Source |
| AdjustmentsForSharebasedPaymentsUSD | 805,890Source | 883,872Source | 313,214Source | 1,076,438Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | -3,614Source | 6,051Source | 78,171Source | — |
| GeneralAndAdministrativeExpenseUSD | 3,610,652Source | 4,362,117Source | 4,759,205Source | 4,327,334Source |
| InterestPaidClassifiedAsFinancingActivitiesCAD | — | — | — | 19,699Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | 132,908Source | 271,784Source | 71,733Source | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 42,543Source | 42,587Source | 40,922Source | 77,031Source |
| ProceedsFromIssuingSharesUSD | — | 78,500Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | — | 4,362,117Source | 4,759,205Source | — |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.23Source | 0.23Source | 0.23Source | — |
| BasicEarningsLossPerShareUSD per share | -30.35Source | -1.69Source | -42.58Source | -7.24Source |
| DepreciationRightofuseAssetsUSD | 38,415Source | 39,023Source | 35,381Source | 82,802Source |
| DilutedEarningsLossPerShareUSD per share | -30.35Source | -1.69Source | -42.58Source | -7.24Source |
| EmployeeBenefitsExpenseUSD | 66,175Source | 57,340Source | 37,838Source | 125,975Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 81,786Source | 132,502Source | 243,717Source | — |
| FinanceCostsCAD | — | — | — | 837,473Source |
| GeneralAndAdministrativeExpenseUSD | 3,610,652Source | 4,362,117Source | 4,759,205Source | 4,327,334Source |
| IncomeTaxExpenseContinuingOperationsUSD | 70,445Source | 377,966Source | 17,372Source | 40,754Source |
| InterestExpenseUSD | 3,857Source | 5,386Source | — | 19,678Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 3,858Source | 5,386Source | 40,922Source | 96,730,000,000Source |
| NetForeignExchangeLossUSD | — | — | 3,684Source | 45,605Source |
| OtherIncomeUSD | — | — | 16,555Source | — |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | — | — | 13,988Source | 42,526Source |
| ProfessionalFeesExpenseUSD | 1,640,621Source | 1,998,625Source | 2,210,795Source | 1,493,024Source |
| ProfitLossBeforeTaxUSD | -3,786,538Source | -4,876,712Source | -8,603,465Source | -9,370,052Source |
| ProfitLossFromOperatingActivitiesCAD | — | — | — | -8,532,579Source |
| ResearchAndDevelopmentExpenseUSD | 2,056,525Source | 1,382,808Source | 1,544,229Source | 4,205,245Source |
Filing attachments
ea030637501ex99-1.htm · 6-K · 2026-09-23
Exhibit 99.1 Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression and PTSD as well as substance use disorders Vancouver, Canada, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing n…
Read attachment ↗